Payment overview · 2025
General Payments
$341.47
19 reported records · 9 companies
Healthcare provider profile · identity verified
Lisa Centilli, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MYRTLE BEACH, SC · NPI 1033417522
Verified facts
What the public records show
CMS Open Payments records show Lisa Centilli, D.O. received $341.47 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $92.57 | 27.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.05 | 14.4% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $42.78 | 12.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.31 | 11.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.10 | 10.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.82 | 8.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.41 | 6.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.73 | 5.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.70 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $341.47 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $92.57 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $49.05 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $49.05 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $49.05 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $42.78 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.31 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.10 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.73 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 309 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 224 | 60 |
| Losartan Potassium | Losartan Potassium | 185 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 158 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 52 |
| Lisinopril | Lisinopril | 154 | 46 |
| Trazodone Hcl | Trazodone Hcl | 137 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 130 | 36 |
| Gabapentin | Gabapentin | 125 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 36 |
| Metformin Hcl | Metformin Hcl | 117 | 32 |
| Omeprazole | Omeprazole | 115 | 38 |
| Simvastatin | Simvastatin | 97 | 28 |
| Meloxicam | Meloxicam | 96 | 27 |
| Sertraline Hcl | Sertraline Hcl | 86 | 26 |
| Prednisone | Prednisone | 77 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 38 |
| Montelukast Sodium | Montelukast Sodium | 70 | 28 |
| Bupropion Xl | Bupropion Hcl | 66 | 18 |
| Eliquis | Apixaban | 64 | 17 |
| Buspirone Hcl | Buspirone Hcl | 60 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 27 |
| Synthroid | Levothyroxine Sodium | 54 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 14 |
| Ozempic | Semaglutide | 50 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 13 |
| Alprazolam | Alprazolam | 40 | 12 |
| Valacyclovir | Valacyclovir Hcl | 39 | 17 |
| Azithromycin | Azithromycin | 37 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 18 |
| Tramadol Hcl | Tramadol Hcl | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | 11 |
| Chlorthalidone | Chlorthalidone | 35 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 34 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 25 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 13 |
| Carvedilol | Carvedilol | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Furosemide | Furosemide | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 11 |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 15 |
| Famotidine | Famotidine | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | 12 |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $341.47 · 19 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, VOQUEZNA, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error